Emergent Biosolutions
EBS
203 hedge funds and large institutions have $1.15B invested in Emergent Biosolutions in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 93 increasing their positions, 64 reducing their positions, and 42 closing their positions.
256% more call options, than puts
Call options by funds: $4.18M | Put options by funds: $1.17M
45% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 64
12% more capital invested
Capital invested by funds: $1.02B → $1.15B (+$124M)
1.11% less ownership
Funds ownership: 91.61% → 90.5% (-1.1%)
9% less funds holding
Funds holding: 224 → 203 (-21)
43% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.8M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.2M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$10.1M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.29M |
| 5 |
AAM
Aberdeen Asset Management
Aberdeen,
United Kingdom
|
+$7.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$17.7M |
| 2 |
D.E. Shaw & Co
New York
|
-$8.98M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$8.97M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.65M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$8.11M |
EBS Hedge Fund Activity: Q3 2016 in Review
203 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2016, worth a combined $1.15B — up 12% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of EBS and 24 opened new positions — a net loss of 18 holders — while 64 trimmed existing stakes and 93 added.
The largest buyer was State Street, adding an estimated $13.8M. The largest seller was Morgan Stanley, cutting an estimated $17.7M.
- 203 institutional investors held Emergent Biosolutions (EBS) as of Q3 2016, down from 224 in Q2 2016.
- Funds reported $1.15B of Emergent Biosolutions stock for Q3 2016, up 12% quarter-over-quarter.
- 24 funds opened new Emergent Biosolutions positions in Q3 2016 and 42 closed out, a net change of -18 holders.
- The largest Emergent Biosolutions buyer in Q3 2016 was State Street, an estimated $13.8M added.
- The largest Emergent Biosolutions seller in Q3 2016 was Morgan Stanley, an estimated $17.7M sold.
Based on aggregated 13F filings for Q3 2016.